Your session is about to expire
← Back to Search
Selinexor for Multiple Myeloma
Study Summary
This trial is testing a new combination of drugs for patients with relapsed or refractory myeloma. The goal is to find the best doses of the drugs and to see if the combination is effective.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 116 Patients • NCT02025985Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the primary conditions that Selinexor is used to treat?
"Selinexor is most often used to treat synovitis, though it can also be effective in treating ophthalmia, sympathetic, branch retinal vein occlusion, and macular edema."
Could you tell me how many individuals are taking part in this research project?
"Unfortunately, this clinical trial is not enrolling patients at the moment. However, there are 826 other trials concerning multiple myeloma and 933 studies involving Selinexor that are presently looking for participants."
What other medical research has been done on Selinexor in the past?
"Selinexor was first trialled in 1997 at Spectrum Health Hospital - Butterworth Campus. There have been a total of 1720 completed clinical trials since then. There are 933 live trials as of now, with a large portion of these taking place in Tampa, Florida."
Are investigators still looking for people to join this research project?
"Although this specific trial is not currently looking for patients, the most recent update on clinicaltrials.gov (from July 26th, 2022) indicates that it was originally posted on September 23rd, 2014. Additionally, there are 1759 other medical trials that are actively recruiting patients."
Share this study with friends
Copy Link
Messenger